AcelRx Pharmaceuticals

391 articles with AcelRx Pharmaceuticals

• AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023

  3/21/2023

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced that it will release full year and fourth quarter financial results for 2022 after the market close on Thursday, March 30, 2023.

• AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals

  3/14/2023

   AcelRx Pharmaceuticals, Inc. today announced the divestment of its FDA-approved drug, DSUVIA® to Alora Pharmaceuticals (Alora). 

• AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures

  3/1/2023

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx) today announced the publication of a report arising from a series of rhinology procedures successfully performed using sufentanil sublingual tablet 30 mcg (SST; DSUVIA) in Otolaryngology Case Reports.

• AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock

  12/27/2022

  AcelRx Pharmaceuticals, Inc. announced it has entered into an agreement with a life sciences-focused investment fund for the sale of 748,744 shares of its common stock, pre-funded warrants exercisable for an aggregate of 2,632,898 shares of common stock and common warrants exercisable for an aggregate of 4,227,052 shares of common stock.

• AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/14/2022

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its third quarter 2022 financial results.

• AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022

  11/3/2022

  AcelRx Pharmaceuticals, Inc. today announced that it will release third quarter financial results after market close on Monday, November 14, 2022.

• AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022

  10/31/2022

  AcelRx Pharmaceuticals, Inc. today announced that an abstract, entitled, "Experience in Complex Outpatient Plastic Surgery Procedures Using Sufentanil Sublingual Tablets" was presented on Friday, October 28th by Jeffrey DeWeese, M.D., FACS, at Plastic Surgery The Meeting 2022, held October 27-30, in Boston, MA.

• AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant

  10/27/2022

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx) today announced that its commercial partner, Laboratorie Aguettant ("Aguettant"), has launched DZUVEO® (sufentanil sublingual tablet, 30 mcg), which is branded as DSUVIA® in the U.S., across Europe.

• AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results

  10/26/2022

  AcelRx Pharmaceuticals, Inc. today announced that the results of a 190-patient, investigator-initiated trial conducted at Brigham and Women's Hospital in Boston, MA, entitled, "The Impact of Sublingual Sufentanil on Postoperative Pain Control in Patients Undergoing Spine Surgery" (abstract # A4262), was presented at the ANESTHESIOLOGY® 2022 annual meeting, held October 21-25, 2022 in New Orleans, LA.

• AcelRx Pharmaceuticals Announces ANESTHESIOLOGY® 2022 Annual Meeting Presentation on DSUVIA® for Battlefield Analgesia by the Uniformed Services University of the Health Sciences

  10/25/2022

  AcelRx Pharmaceuticals, Inc. today announced that an abstract entitled, "Evolution Of Opioid Analgesia On The Battlefield For Moderate-to-Severe Acute Pain" (abstract # A4123) was presented by lead author, Sharon Kim, M.S., at the ANESTHESIOLOGY® 2022 annual meeting, held October 21-25, 2022 in New Orleans, LA.

• AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference

  9/6/2022

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), today announced that Chief Executive Officer, Vince Angotti will present in-person and be available for one-on-one meetings throughout the H.C. Wainwright Annual Investment Conference.

• AcelRx Pharmaceuticals Announces a Second Abstract on DSUVIA® Accepted for Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting

  8/25/2022

  AcelRx Pharmaceuticals, Inc. today announced that an abstract entitled, "Evolution Of Opioid Analgesia On The Battlefield For Moderate-to-Severe Acute Pain" (abstract # A4123) was accepted for e-Abstract presentation at the ANESTHESIOLOGY® 2022 annual meeting, being held October 21-25, 2022 in New Orleans, LA.

• AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022

  8/11/2022

  AcelRx Pharmaceuticals, Inc. today announced that an abstract, entitled, "Experience in Complex Outpatient Plastic Surgery Procedures Using Sufentanil Sublingual Tablets" has been accepted for podium presentation at Plastic Surgery: The Meeting 2022, taking place October 27-30, 2022 in Boston, MA.

• AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  8/11/2022

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its second quarter 2022 financial results.

• AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting

  8/10/2022

  AcelRx Pharmaceuticals, Inc. today announced that an abstract, entitled, "The Impact of Sublingual Sufentanil on Postoperative Pain Control in Patients Undergoing Spine Surgery" (abstract # A4262) was accepted for e-Abstract presentation at the ANESTHESIOLOGY® 2022 annual meeting, being held October 21-25, 2022 in New Orleans, LA.

• AcelRx to Host Second Quarter 2022 Financial Results Call and Webcast on August 11, 2022

  7/28/2022

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Thursday, August 11, 2022.

• AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference

  5/20/2022

  AcelRx Pharmaceuticals, Inc. today announced that Chief Executive Officer, Vince Angotti will present in-person and be available for one-on-one meetings throughout the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Miami, FL.

• AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA®

  5/19/2022

  AcelRx Pharmaceuticals, Inc. today reported that the U.S. Food and Drug Administration (FDA) has recently modified the DSUVIA Risk Evaluation and Mitigation Strategies (REMS) requirements with respect to healthcare setting audits.

• AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

  5/16/2022

  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter 2022 financial results.

• AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia

  5/10/2022

  AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), today announced the publication of clinical data from an investigator-initiated trial in patients undergoing lengthy plastic surgery procedure where use of a single sufentanil sublingual tablet 30 mcg (SST; DSUVIA®) in conjunction with intravenous (IV) opioids was able to dramatically reduce postoperative opioid requirements compared to an equivalent dose of opioids administered only via the IV route.